{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:17:47Z","timestamp":1789107467430,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.esmoop.2025.105514","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:46:35Z","timestamp":1752626795000},"page":"105514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients"],"prefix":"10.1016","volume":"10","author":[{"given":"E.A.","family":"Martino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Carid\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-463X","authenticated-orcid":false,"given":"D.","family":"Lofaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Labanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mendicino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Olivito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1016-3597","authenticated-orcid":false,"given":"N.","family":"Puccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9047-5912","authenticated-orcid":false,"given":"A.","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Amodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-0726","authenticated-orcid":false,"given":"M.","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.105514_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up (dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105514_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105514_bib3","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"10068","key":"10.1016\/j.esmoop.2025.105514_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105514_bib5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"IMROZ Study Group. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105514_bib6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105514_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105514_bib8","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105514_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1517\/13543784.2015.1065250","article-title":"Ixazomib for the treatment of multiple myeloma","volume":"24","author":"Gentile","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105514_bib10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hon.3035","article-title":"Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials","volume":"40","author":"Martino","year":"2022","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105514_bib11","first-page":"846","article-title":"Immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"17","author":"Raza","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105514_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14656566.2016.1274973","article-title":"Pomalidomide in multiple myeloma","volume":"18","author":"Uccello","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105514_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14712598.2023.2193289","article-title":"Isatuximab in multiple myeloma","volume":"23","author":"Martino","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105514_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14712598.2022.2145882","article-title":"Elotuzumab in multiple myeloma","volume":"23","author":"Bruzzese","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105514_bib15","first-page":"245","article-title":"Elotuzumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials","volume":"109","author":"Gentile","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105514_bib16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/hon.3031","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials","volume":"40","author":"Bruzzese","year":"2022","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105514_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3324\/haematol.2019.241513","article-title":"Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials","volume":"106","author":"Gentile","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105514_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104084","article-title":"Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients","volume":"10","author":"Martino","year":"2025","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105514_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14712598.2024.2357382","article-title":"Anti-CD38 monoclonal antibodies in multiple myeloma with gain\/amplification of chromosome arm 1q: a review of the literature","volume":"24","author":"Barbieri","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105514_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70042","article-title":"Efficacy and prognostic indicators of isatuximab, pomalidomide, and dexamethasone (IsaPd) in daratumumab-refractory multiple myeloma patients: a multicenter real-world study","volume":"43","author":"Martino","year":"2025","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105514_bib21","first-page":"275","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105514_bib22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/ejh.14121","article-title":"Teclistamab-cqyv in multiple myeloma","volume":"112","author":"Martino","year":"2024","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105514_bib23","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14712598.2023.2218543","article-title":"Belantamab mafodotin in multiple myeloma","volume":"23","author":"Martino","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105514_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105514_bib25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"10249","key":"10.1016\/j.esmoop.2025.105514_bib26","first-page":"466","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105514_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10262","key":"10.1016\/j.esmoop.2025.105514_bib28","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105514_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105514_bib30","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105514_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.643490","article-title":"Treatment of lenalidomide exposed or refractory multiple myeloma: network meta-analysis of lenalidomide-sparing regimens","volume":"11","author":"Botta","year":"2021","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105514_bib32","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.esmoop.2025.105514_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"Br Med J"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105514_bib34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105514_bib35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4161\/cbt.28557","article-title":"Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials","volume":"15","author":"Staropoli","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105514_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0895-4356(92)90085-2","article-title":"Incorporating variations in the quality of individual randomized trials into meta-analysis","volume":"45","author":"Detsky","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.esmoop.2025.105514_bib37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"7109","key":"10.1016\/j.esmoop.2025.105514_bib38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105514_bib39","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105514_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105514_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105514_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","article-title":"Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report","volume":"17","author":"Jansen","year":"2014","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105514_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"issue":"10292","key":"10.1016\/j.esmoop.2025.105514_bib64","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105514_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"key":"10.1016\/j.esmoop.2025.105514_bib45","series-title":"Poster presented at the European Hematology Association (EHA) Hybrid Congress","article-title":"Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA study","author":"Facon","year":"2024"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105514_bib46","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105514_bib47","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105514_bib48","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105514_bib49","doi-asserted-by":"crossref","first-page":"TPS8069","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8069","article-title":"EXCALIBER-RRMM: a phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Lonial","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105514_bib50","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/S2152-2650(23)01446-5","article-title":"MM-372 a phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed\/refractory multiple myeloma (RRMM): SUCCESSOR-1","volume":"23","author":"Richardson","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105514_bib51","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105514_bib52","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105514_bib53","doi-asserted-by":"crossref","unstructured":"Mateos MV, San-Miguel J, Dhakal B, et al. Overall survival (OS) with ciltacabtagene autoleucel (Cilta-cel) versus standard of care (SoC) in lenalidomide (Len)-refractory multiple myeloma (MM): phase 3 CARTITUDE-4 study update. Poster presented at the 2024 International Myeloma Society Annual Meeting. September 25-28, 2024; Rio de Janeiro, Brazil. Abstract OA\u201365.","DOI":"10.1016\/S2152-2650(24)02346-2"},{"key":"10.1016\/j.esmoop.2025.105514_bib54","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105514_bib55","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2025.105514_bib56","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105514_bib57","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/ejh.14353","article-title":"Talquetamab in multiple myeloma: efficacy, safety, and future directions","volume":"114","author":"Labanca","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.esmoop.2025.105514_bib58","doi-asserted-by":"crossref","first-page":"TPS8072","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072","article-title":"MajesTEC-3: randomized, phase 3 study of teclistamab plus daratumumab versus investigator\u2019s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Mateos","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105514_bib59","doi-asserted-by":"crossref","first-page":"TPS8074","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8074","article-title":"MagnetisMM-5: an open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Grosicki","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105514_bib60","doi-asserted-by":"crossref","first-page":"TPS8067","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8067","article-title":"MajesTEC-9: a randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Touzeau","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105514_bib61","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8070","article-title":"A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed\/refractory multiple myeloma (RRMM): SUCCESSOR-2","volume":"41","author":"Richardson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105514_bib62","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1182\/blood-2024-207377","article-title":"MagnetisMM-32: evaluation of elranatamab Vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38-directed therapy","volume":"144","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105514_bib63","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41408-024-01034-6","article-title":"Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis","volume":"14","author":"Hoff","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925013833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925013833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:13:05Z","timestamp":1759612385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925013833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2059702925013833"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105514","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105514"}}